Source - LSE Regulatory
RNS Number : 6159E
Hemogenyx Pharmaceuticals PLC
30 June 2023
 

30 June 2023

 

Hemogenyx Pharmaceuticals plc 

("Hemogenyx Pharmaceuticals" or the "Company")

 

Result of Annual General Meeting

 

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed on a show of hands. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below.

 

Proxy Voting Results

Ordinary Resolutions

Votes for

% of votes cast for

Votes Against

% of votes cast against

Total votes cast

Total votes cast as % of ISC (1)

Votes with-held (2)

1. To adopt the 2022 Annual Report and Accounts​

187,231,295

99.86

260,529

0.14

187,491,824

16.42

4,905,675

2. To approve the Directors' Remuneration Policy​

175,511,893

91.34

16,644,001

8.66

192,155,894

16.83

241,605

3. To re-appoint Peter Redmond as Director

161,957,826

86.38

25,531,232

13.62

187,489,058

16.42

4,908,441

4. To re-appoint Alexis Sandler as Director

175,078,447

93.44

12,285,451

6.56

187,363,898

16.41

5,033,601

5. To re-appoint Dr Vladislav Sandler as Director

175,160,284

93.49

12,203,614

6.51

187,363,898

16.41

5,033,601

6. To reappoint the Company's auditor

185,776,647

99.09

1,715,177

0.91

187,491,824

16.42

4,905,675

7.​ To authorise the Audit Committee to determine the auditor's remuneration​

176,309,143

94.04

11,179,915

5.96

187,489,058

16.42%

4,908,441

8. To authorise the Directors to allot equity securities​

170,229,487

90.79

17,259,571

9.21

187,489,058

16.42

4,908,441

Special Resolutions

Votes for

% of votes cast for

Votes against

% of votes cast against

Total votes cast

Total votes cast as % of ISC (1)

Votes with-held (2)

9. To disapply pre-emption provisions​

156,025,169

89.79

17,751,132

10.21

173,776,301

15.22

18,621,198

10. To reduce the notice period for general meetings

171,582,521

91.51

15,909,303

8.49

187,491,824

16.42

4,905,675

 

(1)        The Company's issued share capital ("ISC") on 28 June 2023, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 1,141,999,321 ordinary shares.

(2)        A 'vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.

 

A copy of the resolutions passed has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

Enquiries:

 

Hemogenyx Pharmaceuticals plc

https://hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

headquarters@hemogenyx.com

Peter Redmond, Director

peter.redmond@hemogenyx.com





SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Adam Cowl







Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow



 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGNKKBKPBKDAAN
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Hemogenyx Pharmaceuticals PLC (HEMO)

+0.02p (+1.37%)
delayed 15:52PM